A randomized, double-blind, placebo-controlled, proof of concept, antipruritic study of the neurokinin-1 receptor antagonist VLY-686 in subjects with treatment-resistant pruritus associated with atopic dermatitis.

Trial Profile

A randomized, double-blind, placebo-controlled, proof of concept, antipruritic study of the neurokinin-1 receptor antagonist VLY-686 in subjects with treatment-resistant pruritus associated with atopic dermatitis.

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jun 2015

At a glance

  • Drugs Tradipitant (Primary)
  • Indications Pruritus
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Vanda Pharmaceuticals
  • Most Recent Events

    • 04 Mar 2015 Primary endpoint has not been met (efficacy of tradipitant [VLY-686] on reducing chronic pruritus using Visual Analog Scale (VAS)), according to a Vanda Pharmaceuticals media release.
    • 04 Mar 2015 Top-line results published in a Vanda Pharmaceuticals media release.
    • 04 Mar 2015 Status changed from recruiting to completed, as reported in a Vanda Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top